Remove Cannabinoids Remove Pharmaceutical Remove Treatment
article thumbnail

Cannabinoids for Scleroderma

Project CBD

Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma.

article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Additional information regarding cannabinoids and pain appears online h ere.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Cannabis Cancer Connection

Project CBD

There is a growing body of anecdotal and scientific evidence that the “major cannabinoids” tetrahydrocannabinol (THC) and cannabidiol (CBD), certain “minor cannabinoids” (some without a name), and other cannabis compounds have antineoplastic action against cancer cells. THC binds to two types of cannabinoid receptors, CB1 and CB2.

article thumbnail

Medical Marijuana Offers Hope for Treatment of PTSD

FloridaMarijuana.net

Treatment usually aims at reducing reactions and to diminishing the acuity of the reactions. Treatments also seek to increase the subject’s ability to manage trauma-related emotions and to greater confidence in coping abilities. The endocannabinoid system consists of cannabinoid receptors all over the body.

Treatment 182
article thumbnail

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

article thumbnail

This app-guided psychedelic treatment works when antidepressants don’t

The Cannigma

When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment?

Treatment 138